Amundi Decreases Stock Position in Johnson & Johnson $JNJ

Key Points

• Amundi reduced its Johnson & Johnson stake by 2.2% in the second quarter, selling 289,163 shares and retaining 13.1 million shares worth approximately $3.33 billion. Institutional investors collectively own 69.55% of J&J.
• J&J reported quarterly earnings and revenue above expectations, with revenue up 6.6% year over year, and maintains a $5.36 annual dividend yielding about 2.0%. Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $274.13 price target.
• Potential catalysts include a reported sale or spinoff of the DePuy Synthes orthopedics business and strong Rybrevant lung-cancer results, while risks include a failed Phase 2 depression-drug trial, Stelara biosimilar competition, and continued insider selling.

Amundi decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,117,657 shares of the company's stock after selling 289,163 shares during the quarter. Johnson & Johnson makes up 0.8% of Amundi's portfolio, making the stock its 17th biggest position. Amundi owned 0.54% of Johnson & Johnson worth $3,331,491,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Brown Financial Advisors raised its stake in Johnson & Johnson by 10.6% during the second quarter. Brown Financial Advisors now owns 7,216 shares of the company's stock valued at $1,833,000 after buying an additional 694 shares in the last quarter. Advus Financial Partners LLC increased its stake in Johnson & Johnson by 4.5% during the second quarter. Advus Financial Partners LLC now owns 7,402 shares of the company's stock valued at $1,880,000 after purchasing an additional 317 shares during the last quarter. Groupe la Francaise raised its holdings in shares of Johnson & Johnson by 991.4% during the second quarter. Groupe la Francaise now owns 198,681 shares of the company's stock worth $50,466,000 after purchasing an additional 180,477 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Johnson & Johnson in the 2nd quarter worth about $207,865,000. Finally, Carlson Financial Inc. boosted its holdings in shares of Johnson & Johnson by 3.6% in the 2nd quarter. Carlson Financial Inc. now owns 3,288 shares of the company's stock valued at $835,000 after buying an additional 115 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Potential $20 billion DePuy Synthes sale could unlock value. Apollo Global Management is reportedly in talks to acquire J&J’s DePuy Synthes orthopedics business, which generated approximately $9.3 billion in 2025 revenue. A sale or spinoff could sharpen J&J’s focus and return capital to shareholders. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Positive Sentiment: Rybrevant delivers strong lung-cancer results. J&J reported that Rybrevant plus chemotherapy produced a 34.3-month median overall survival in EGFR exon 20 insertion-positive non-small-cell lung cancer, described as the longest reported result for this population. Separate data also showed fewer treatment-related events with the Rybrevant Faspro and Lazcluze combination, supporting the oncology pipeline and potential commercial momentum. Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
• Positive Sentiment: Analyst and defensive-investment support remain favorable. TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and the possible DePuy Synthes transaction. J&J is also being highlighted as a reliable dividend and defensive healthcare holding, which may attract investors during market volatility. J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Buy Rating
• Neutral Sentiment: Investors are monitoring strategic and fundamental developments. Attention is focused on J&J’s ability to achieve double-digit growth while Stelara faces biosimilar competition. Recent institutional activity has been mixed, while reported insider transactions consisted entirely of sales over the past six months.
• Negative Sentiment: Clinical setback hits a partnered depression treatment. JNJ-5120, also known as PIPE-307, failed to meet the primary endpoint in the Phase 2 MOONLIGHT-1 trial for major depressive disorder. J&J is reviewing additional data, but the failure reduces confidence in this portion of its drug-development pipeline. Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Bank of America increased their price target on Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a research report on Friday, July 10th. Morgan Stanley upped their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research note on Thursday, July 16th. Citigroup raised their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, Royal Bank Of Canada lifted their price target on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $274.13.

Johnson & Johnson Stock Up 0.2%

Johnson & Johnson stock opened at $266.94 on Wednesday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The stock has a market cap of $643.29 billion, a price-to-earnings ratio of 30.93, a PEG ratio of 2.54 and a beta of 0.24. The company's 50-day moving average price is $263.17 and its two-hundred day moving average price is $246.23. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts expect that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio is 62.11%.

Insider Transactions at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.